Validation of CT iodine mapping for lobar perfusion assessment
Research type
Research Study
Full title
Lobar Segmented Iodine Mapping of the Lungs using Dual Energy Computed Tomography in Advanced Chronic Obstructive Pulmonary Disease
IRAS ID
265630
Contact name
CA Ridge
Contact email
Sponsor organisation
Royal Brompton & Harefield NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
The key to success in lung volume reduction (LVR) therapy for chronic obstructive pulmonary disease (COPD) is accurate patient selection. The ideal candidate is one who has (1) emphysema which is concentrated in one anatomic area (usually the upper lung or "lobe") and (2) that lobe must receive very little blood flow. Patients are selected using two separate tests, computed tomography (CT) and perfusion scintigraphy (VQ), which is typically performed on separate days. CT quantifies the severity and distribution of emphysema and VQ assesses technetium distribution (a surrogate for blood flow) to each lobe. VQ is typically performed for these patients as part of routine clinical care in a specialist centre and carries with it a higher cost compared to CT. However, dual energy CT (DECT) can be used to perform both the initial CT test, and the second blood flow assessment simultaneously by injecting x-ray dye which contains iodine during the CT scan. Known as CT perfusion mapping, the technology creates a "iodine map" of blood flow to the lungs provides a one-stop answer to the two questions posed. We propose to validate its performance in the assessment of adult patients who have been referred to the Royal Brompton Hospital for lung volume reduction assessment between March 22, 2018 to February 28, 2020.
REC name
N/A
REC reference
N/A